Condensed Consolidated Statements of Operations (Unaudited) - USD ($) $ in Thousands		3 Months Ended
		Mar. 31, 2017		Mar. 31, 2016
Revenues:
Royalties		$ 24,230		$ 14,390
Material sales		1,121		5,341
License fees, milestones and other revenues		3,916		9,917
Total revenues		29,267		29,648
Operating costs and expenses:
Cost of sales	[1]	341		955
Amortization of intangibles		2,715		2,524
Research and development		8,673		4,004
General and administrative		7,322		7,069
Total operating costs and expenses		19,051		14,552
Income from operations		10,216		15,096
Other (expense) income:
Interest expense, net		(2,941)		(3,005)
Increase in contingent liabilities		(140)		(1,306)
Loss from Viking		(1,083)		(1,605)
Other income, net		141		391
Total other expense, net		(4,023)		(5,525)
Income before income taxes		6,193		9,571
Income tax expense		(1,114)		(3,694)
Income from operations		5,079		5,877
Gain on sale of Oncology Product Line before income taxes		0		1,139
Income tax expense on discontinued operations		0		(408)
Income from discontinued operations		0		731
Net income		$ 5,079		$ 6,608
Basic earnings per share data(2)
Income from continuing operations (in usd per share)	[2]	$ 0.24		$ 0.28
Income from discontinued operations (in usd per share)	[2]	0.00		0.04
Net income (in usd per share)	[2]	0.24		0.32
Diluted earnings per share data (2)
Income from continuing operations (in usd per share)	[2]	0.22		0.26
Income from discontinued operations (in usd per share)	[2]	0.00		0.03
Net income (in usd per share)		$ 0.22	[2]	$ 0.30
Shares used for computation (in thousands)
Basic (in shares)		20,938,000		20,708,000
Diluted (in shares)		23,019,189		22,283,979

[1] Excludes amortization of intangibles.

[2] The sum of net income per share amounts may not equal the totals due to rounding.